Physician profile
Gilbert N Egekeze
NPI 1548361959
$6,249.40
in general payments reported to CMS, 2019-2025
38 companies · $1,020 in 2025
The $1,020 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $657 · 2020: $804 · 2021: $1,333 · 2022: $585 · 2023: $823 · 2024: $1,027 · 2025: $1,020.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,806 · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,805.61 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,265.96 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $951.48 | 2020-2025 | |
| Abbvie INC. | $653.14 | 2021-2025 | Linzess, Viberzi |
| Glaxosmithkline, LLC. | $402.18 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $347.46 | 2019-2025 | Xarelto, Spravato |
| Astrazeneca Pharmaceuticals LP | $256.96 | 2019-2025 | |
| Amarin Pharma, INC. | $206.23 | 2020-2021 | |
| Abbott Laboratories | $181.57 | 2024-2025 | Freestyle Libre 3, Eterna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $167.56 | 2019-2024 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.14 | 2019-2024 | Jardiance |
| Allergan, INC. | $146.16 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $143.88 | 2023-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $119.58 | 2019-2025 | Eliquis, Camzyos |
| Astellas Pharma US INC | $116.95 | 2020-2025 | Veozah |
| Lilly USA, LLC | $109.93 | 2020-2025 | Zepbound, Mounjaro, Emgality |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gilbert Egekeze listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.